Ryosuke Hirohata
Overview
Explore the profile of Ryosuke Hirohata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ohsawa M, Nishi H, Emi M, Yoshikawa T, Hamai Y, Ibuki Y, et al.
J Radiat Res
. 2024 Dec;
65(Supplement_1):i126-i134.
PMID: 39679879
Despite advances in multimodality therapy, including surgery, chemotherapy, radiation therapy and chemoradiation, the fatality rate for esophageal cancer remains high. Specifically, Fusobacterium nucleatum, due to its aggregation capacity, has shown...
2.
Hirohata R, Yamamoto Y, Mimae T, Hamai Y, Ibuki Y, Takahashi R, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):789-790.
PMID: 39546104
No abstract available.
3.
Hamai Y, Ibuki Y, Kurokawa T, Hirohata R, Ohsawa M, Kitasaki N, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456623
Background: Patients across various cancers who develop immune-related adverse events (irAEs) post-immune checkpoint inhibitor (ICI) treatment tend to experience better tumor response and survival than those who do not. However,...
4.
Hirohata R, Yamamoto Y, Mimae T, Hamai Y, Ibuki Y, Takahashi R, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):570-580.
PMID: 39419890
Background: The authors hypothesized that small ribonucleic acid (sRNA) obtained from blood samples after neoadjuvant therapy from patients treated with neoadjuvant chemoradiation therapy (NACRT) could serve as a novel biomarker...
5.
Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Hirohata R, et al.
Surgery
. 2024 Oct;
178():108863.
PMID: 39419644
Background: Patients diagnosed with pathologic T1N0 esophageal squamous cell carcinoma and treated with surgery alone have a good prognosis and are generally followed up without adjuvant therapy. However, recurrence has...
6.
Hirohata R, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Ohsawa M, et al.
World J Surg
. 2024 May;
48(7):1700-1709.
PMID: 38757868
Background: Prognosis of patients who achieve pathological complete response (pCR) with neoadjuvant therapy (NAT) is better than that of non-pCR patients. Currently, there is no indication for adjuvant immune checkpoint...
7.
Emi M, Hamai Y, Yoshikawa T, Hirohata R, Ohsawa M, Kurokawa T, et al.
Cancer Diagn Progn
. 2024 May;
4(3):276-280.
PMID: 38707736
Background/aim: This study aimed to evaluate the long-term prognosis of definitive chemoradiotherapy and clinical features of postoperative lymph node (LN) recurrence after curative resection of thoracic esophageal squamous cell cancer...
8.
Ohsawa M, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, et al.
World J Surg
. 2024 Apr;
48(3):650-661.
PMID: 38686781
Background: There are few reports on the associations between lymph node (LN) status, determined by preoperative F-fluorodeoxyglucose-positron emission tomography (FDG-PET), and prognosis in patients with locally advanced esophageal squamous cell...
9.
Hamai Y, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Kurokawa T, et al.
World J Surg
. 2024 Feb;
48(2):416-426.
PMID: 38310312
Background: Pathological lymph node metastasis (LNM) following multimodal therapy is an important indicator of poor prognosis in patients with esophageal cancer. However, a significant number of patients without LNM are...
10.
Hirohata R, Hamai Y, Murakami Y, Emi M, Nishibuchi I, Kurokawa T, et al.
J Thorac Dis
. 2023 Nov;
15(10):5319-5329.
PMID: 37969281
Background: Esophageal fistula (EF) is a serious complication in patients with cT4b esophageal squamous cell carcinoma (ESCC) with adjacent organ involvement. Among EFs, aortoesophageal fistula (AEF), forming a fistula with...